Key concepts in biosimilar medicines: What physicians must know

Area of Science:

• Biotechnology
• Pharmacology
• Immunology

Background:

• Biologics, produced via recombinant DNA technology, are vital in rheumatology and oncology.
• The escalating cost of biologics presents a significant challenge, especially with expanding use in immune-mediated inflammatory diseases.
• Biosimilars, or follow-on biologics, are emerging as a key strategy to address these cost concerns.

Purpose of the Study:

• To summarize essential concepts of biosimilars for physicians.
• To highlight the current status and regulatory considerations of biosimilars.
• To provide an overview relevant to the Turkish healthcare landscape.

Main Methods:

• Literature review of biosimilar concepts and regulatory guidelines.
• Analysis of the definition and criteria for biosimilarity.
• Focus on the Turkish market context for biosimilars.

Main Results:

• Biosimilars are defined as highly similar to reference biologics.
• No clinically meaningful differences in safety, purity, and potency are required for biosimilar approval.
• The review synthesizes key information for clinical application.

Conclusions:

• Biosimilars represent a significant opportunity for cost savings in biologic therapy.
• Understanding biosimilarity criteria is crucial for physicians adopting these alternatives.
• The availability and acceptance of biosimilars are expanding globally, including in Turkey.